Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

138 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
TAILOR - tapered discontinuation versus maintenance therapy of antipsychotic medication in patients with newly diagnosed schizophrenia or persistent delusional disorder in remission of psychotic symptoms: study protocol for a randomized clinical trial.
Stürup AE, Jensen HD, Dolmer S, Birk M, Albert N, Nielsen M, Hjorthøj C, Eplov L, Ebdrup BH, Mors O, Nordentoft M. Stürup AE, et al. Among authors: ebdrup bh. Trials. 2017 Sep 29;18(1):445. doi: 10.1186/s13063-017-2172-4. Trials. 2017. PMID: 28962668 Free PMC article. Clinical Trial.
Progressive striatal and hippocampal volume loss in initially antipsychotic-naive, first-episode schizophrenia patients treated with quetiapine: relationship to dose and symptoms.
Ebdrup BH, Skimminge A, Rasmussen H, Aggernaes B, Oranje B, Lublin H, Baaré W, Glenthøj B. Ebdrup BH, et al. Int J Neuropsychopharmacol. 2011 Feb;14(1):69-82. doi: 10.1017/S1461145710000817. Epub 2010 Aug 12. Int J Neuropsychopharmacol. 2011. PMID: 20701823 Free article. Clinical Trial.
Treatment of antipsychotic-associated obesity with a GLP-1 receptor agonist--protocol for an investigator-initiated prospective, randomised, placebo-controlled, double-blinded intervention study: the TAO study protocol.
Ishøy PL, Knop FK, Broberg BV, Baandrup L, Fagerlund B, Jørgensen NR, Andersen UB, Rostrup E, Glenthøj BY, Ebdrup BH. Ishøy PL, et al. Among authors: ebdrup bh. BMJ Open. 2014 Jan 8;4(1):e004158. doi: 10.1136/bmjopen-2013-004158. BMJ Open. 2014. PMID: 24401727 Free PMC article. Clinical Trial.
Frontal D2/3 Receptor Availability in Schizophrenia Patients Before and After Their First Antipsychotic Treatment: Relation to Cognitive Functions and Psychopathology.
Nørbak-Emig H, Ebdrup BH, Fagerlund B, Svarer C, Rasmussen H, Friberg L, Allerup PN, Rostrup E, Pinborg LH, Glenthøj BY. Nørbak-Emig H, et al. Among authors: ebdrup bh. Int J Neuropsychopharmacol. 2016 Apr 29;19(5):pyw006. doi: 10.1093/ijnp/pyw006. Print 2016 May. Int J Neuropsychopharmacol. 2016. PMID: 26819282 Free PMC article. Clinical Trial.
Effect of GLP-1 receptor agonist treatment on body weight in obese antipsychotic-treated patients with schizophrenia: a randomized, placebo-controlled trial.
Ishøy PL, Knop FK, Broberg BV, Bak N, Andersen UB, Jørgensen NR, Holst JJ, Glenthøj BY, Ebdrup BH. Ishøy PL, et al. Among authors: ebdrup bh. Diabetes Obes Metab. 2017 Feb;19(2):162-171. doi: 10.1111/dom.12795. Epub 2016 Nov 14. Diabetes Obes Metab. 2017. PMID: 27717222 Free PMC article. Clinical Trial.
138 results